Recent breakthroughs spotlight new therapeutic candidates and biomarkers in oncology. Regeneron reported a 100% response rate in a small smoldering multiple myeloma trial with its T-cell engager Lynozyfic. Indiana University researchers identified two protein targets to sensitize pancreatic cancer cells to therapy. Additionally, a Salk Institute study discovered a sugar, HSAT, that slows pancreatic tumor progression and may serve as a biomarker. Advances in understanding genetic drivers such as NUAK2 in glioblastoma and PRMT5 inhibitors in cancer highlight expanding targeted therapy avenues.